Prediction of Chemotherapy Response by Magnetic Resonance Spectroscopy
Abstract
This research seeks to validate the use of MRS to assess therapeutic response in patients with locally-advanced breast cancer receiving primary Systemic therapy (PST), or neoadjuvant chemotherapy. 35 women were enrolled in this study. Magnetic resonance spectroscopy (MRS) scanning was used to measure the tumor concentration of choline-containing compounds TCho, which is known to be elevated in cancers and in proliferating cells. Clinical response was assessed by MRI measurements of tumor size based on the criteria of RECIST (response evaluation criteria in solid tumors). Changes in TCho between the baseline MRS scan (acquired <1 wk before starting PST) and that acquired 24 hours after the 1st dose of PST showed a significant positive correlation with change in tumor size measured after completing PST (R=0.89, p<0.0001). Opposite trends in TCho between objective responders and nonresponders (p=0.0l0l) were observed already at 24 hours after starting PST. These results show that MRS scanning can distinguish responders versus nonresponders early in the course of PST. These findings provide evidence that MRS may be used clinically to individualize treatments for maximizing benefit and to rapidly assess efficacy of new drugs. Findings are being published in Radiology in Fall 2004.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2004
- Accession Number
- ADA430571
Entities
People
- Michael Garwood
Organizations
- University of Minnesota